TearScience<sup>®</sup> LipiFlow<sup>®</sup> is a Meibomian Gland Dysfunction (MGD) Treatment Option for Your Eyelids.

If you have been told that your Dry Eye is MGD, it’s easy to do something about it. The TearScience® LipiFlow® treatment is a safe comfortable, and effective eyelid massage. Best of all, this dry eye treatment option can be done while resting in a chair right in your doctor’s office.

Planning for Surgery?

Consider TearScience® LipiFlow® Treatment Prior to Surgery.

It’s been shown that Dry Eye caused by MGD can cause unsatisfactory vision and affect the overall results of both cataract and LASIK surgery.1 In fact, dry eye symptoms caused by MGD tend to worsen with surgical procedures if they are not treated. The good news is that the TearScience® LipiFlow® treatment can help optimize the ocular surface by stabilizing the tear film prior to surgery.2 In fact, in a recent study, patients treated with TearScience® LipiFlow® had a twofold reduction in dry eye symptoms 3 months after surgery.2

Ready to Trash Your Contact Lenses?

Consider TearScience® LipiFlow® Treatment First.

Do you feel as if your contacts don’t fit correctly or that your vision fluctuates in and out during the day? Contact lens wear is a common condition contributing to dry eye symptoms and MGD. But a single TearScience® LipiFlow® treatment for MGD can increase your average comfortable soft contact lens wear time by up to 4 more hours.3 If you are struggling with your contact lenses, find a doctor near you and get screened for MGD.

TearScience<sup>®</sup> LipiFlow<sup>®</sup> Treatment Massages Your Eyelids to Remove Gland Blockage.

During treatment, you can relax4 while the TearScience® LipiFlow® treatment system helps restore your blocked and obstructed glands, allowing them to secrete the necessary oils that keep your eyes healthy and protected. During treatment, Meibomian glands are heated and then gently massaged to loosen the oil trapped within the glands. This automated treatment helps clear the gland obstruction and restore function.5 Other than an initial topical anesthetic drop prior to treatment, there are no other drugs required for this treatment.

The TearScience® LipiFlow® treatment begins with the placement of the activators on your eyes. It is a simple process that is done with minimal discomfort. The TearScience® LipiFlow® activators are specifically designed to be placed under and over the eyelids. They are single-use sterile devices that deliver automated therapeutic energy to the Meibomian glands in a 12-minute procedure while protecting the delicate structures of your eye, safely and comfortably.

TearScience® LipiFlow® Treatment Works to Restore Gland Oil Production.

After the activators are placed on your eyes, your TearScience® LipiFlow® treatment will begin. During the treatment, the obstructed and blocked Meibomian glands are stimulated with controlled heat and then gently massaged to stimulate trapped oil within the glands to flow. It clears the obstructed glands in your eyelids and helps restore the healthy gland function needed for stable vision and ocular comfort.

The entire TearScience® LipiFlow® treatment takes 12 minutes. When the treatment is performed, the glands can resume normal oil, or lipid production, which is essential for maintaining and protecting a healthy tear film.


What Can You Expect After TearScience® LipiFlow® Treatment?

Results with TearScience® LipiFlow® can be experienced 6 to 8 weeks after treatment and may vary depending on the level of severity of MGD.5 Remember—TearScience® LipiFlow® only treats MGD, a leading underlying cause of Dry Eye, but there may be other factors associated with your disease. Therefore, dry eye symptoms are not expected to fully resolve just with TearScience® LipiFlow®. Dry Eye is a multifactorial condition and may require additional dry eye treatment options. Be sure to talk to your doctor about what’s right for you.

With more than 400,000 TearScience<sup>®</sup> LipiFlow<sup>®</sup> treatments worldwide and growing, patients are experiencing proven benefits of this dry eye treatment option<sup>6</sup>:

  • Long-lasting results; many see the continued benefit for up to 12 months7
  • No pain and/or discomfort reported for the vast majority of patients4

Ready to Treat an Underlying Cause of Your Dry Eyes?

If you suffer from dry eye symptoms and other dry eye treatment options aren’t working, it could be Meibomian Gland Dysfunction (MGD). MGD is a prevalent, chronic, and progressive disease that becomes worse the longer it goes untreated.8-9 Find a doctor near you who can screen you and then treat MGD with our safe, comfortable, and effective eyelid treatment.4


1. Starr CE, Gupta PK, Farid M, et al. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J Cataract Refract Surg. 2019 May;45(5): 669-684. 2.Data on file, 2018 (NCT01808560). Pilot study for treatment of meibomian gland dysfunction (MGD) prior to cataract surgery. Accessed from https://clinicaltrials.gov/show/NCT1808560. 3. Blackie CA, Coleman CA, Nichols KK, et al. A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day. Clin Ophthalmol. 2018 Jan;12:169-183. 4. Lane SS et al. A New System, the LipiFlow, for the Treatment of Meibomian Gland Dysfunction (MGD). Cornea. 2012;31(4):396-404. 5. Blackie CA, Carlson AN, Korb, DR. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. Curr Opin Ophthalmol. 2015 Jul;26(4):306-313. 6. Internal Data on File, 2019. 7. Blackie CA et al. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clinical Ophthalmol. 2016; 10:1385-1396. 8. Nichols KK, Hanlon SD, Nichols JJ. A murine model for characterizing glandular changes in obstructive meibomian gland dysfunction. ARVO. 2014. Abstract #13-A0002. 9. Schaumberg DA, Nichols JJ, Papas EB, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011;3:52(4):1994-2005.